Drug profile · INN
selpercatinib
RETEVMO
selpercatinib (RETEVMO) is a tyrosine-protein kinase receptor ret inhibitor. Route of administration: oral. Current US regulatory status: approved.
Drug details — selpercatinib
- US status
- approved
- Class
- Antineoplastic and immunomodulating agents (L01)
- Route
- ORAL
- Patents
- 0
- Programs
- 9
- Data quality
- 0.84
Quick answer
selpercatinib (RETEVMO) is a tyrosine-protein kinase receptor ret inhibitor. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Tyrosine-protein kinase receptor RET inhibitor
Primary target: Coiled-coil domain-containing protein 6/Tyrosine-protein kinase receptor RET
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
| TGA | approved | — |
| NMPA | clinical trials | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is selpercatinib?
selpercatinib (RETEVMO) is a tyrosine-protein kinase receptor ret inhibitor. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for selpercatinib?
RETEVMO is a marketed brand name for selpercatinib. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of selpercatinib?
selpercatinib has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.